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httpicense.Abstract A validated, simple and sensitive stability-indicating HPLC method was introduced for
the analysis of Pentoxifylline in the presence of its pharmacopeial related substances, Caffeine anhy-
drous and Theophylline anhydrous, in the presence of its forced degradation products. This was
achieved using a gradient DAD–HPLC method in order to achieve a good separation between
the related substance peaks, complying with the pharmacopeial requirement, and an adequate
retention time for the Pentoxifylline peak. The method was validated according to the ICH guide-
lines and different HPLC parameters were optimized for the determination of Pentoxifylline in its
dosage form (sustained release tablets). Furthermore, the study of forced degradation of Pentoxif-
ylline was done under various conditions including; hydrolysis (acid, alkaline and neutral), oxida-
tion, dry heat and photo-decomposition. The proposed method could separate Pentoxifylline peak
from those of the different forced degradation product peaks and the purity of the Pentoxifylline
peak was conﬁrmed using the photo-diode array detector.
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Pentoxifylline (PEN) (Fig. 1a) is a member of Methylxanthines
which are a group of alkaloids commonly used for their effects
as mild stimulants and as bronchodilators.1,2 Methylxanthines
not only affect the airways but stimulate heart rate causing car-
diac arrhythmias at high concentrations.2 Methylated xanth-
ines include many compounds as PEN, Caffeine (CAF)
(Fig. 1b) and Theophylline (THEO) (Fig. 1c). PEN is used in
the treatment of peripheral vascular diseases, to increase bloodaculty of Pharmacy, Cairo University.
3.06.001
Figure 1 Chemical structures of (a) Pentoxifylline (PEN), (b)
Caffeine anhydrous (CAF) and (c) Theophylline anhydrous
(THEO).
212 M.A. Korany et al.ﬂow to ischemic tissues and to improve tissue oxygenation in
patients with peripheral vascular disease.2
The USP 343 monograph of PEN describes an HPLC meth-
od for its assay in pure form and in extended-release tablets,
where a limit for the resolution of PEN and CAF is mentioned
to be not less than 10. However the B.P 20124 monograph of
PEN describes a non aqueous potentiometric titration method
for its analysis in pure form, it also describes an HPLC method
with gradient elution for an analysis of related substances in
PEN and speciﬁes a limit for the resolution between CAF
and THEO not less than 4.
The USP chromatographic system used a four component
mobile phase (perchloric acid, acetonitrile, tetrahydrofuran
and methanol) in the separation of PEN from one related sub-
stance only (CAF). The BP chromatographic system is similar
to the one used in the proposed work at which a gradient elu-
tion of a mobile phase composed of KH2PO4 and methanol is
used in order to separate PEN from its related substances. The
proposed work not only separates PEN from its related sub-
stances (CAF and THEO) but also separates PEN from any
foreign peaks appearing after different forced degradation
studies. That is why the proposed method is considered a sta-
bility indicating method and the DAD was used to conﬁrm the
identity and the purity of the parent drug peak (PEN) as will
be discussed later.
A survey of the literature showed that different analytical
techniques have been reported for the analysis of PEN.
Gas chromatography (GC) method has been used in the
determination of PEN and its major metabolites in human
milk.5 Thin layer chromatographic method (TLC) has been
used for the determination of PEN and its major metabolites.6
High Performance Thin Layer Chromatographic method
(HPTLC) has been also used for in-process purity testing of
PEN and its related substances, impurities and side reaction
products.7
Spectroscopic method was used for the analysis of pharma-
ceutical tablets containing PEN and insoluble excipient.8Electrochemical oxidation was also applied for PEN
determination.9
Micellar electrokinetic chromatography (MEKC) method
has been used for the determination of PEN, Caffeine
anhydrous (CAF) and Theophylline anhydrous (THEO) in
pharmaceutical formulations.10
Spectroﬂuorimetric and spectrophotometric methods have
been used for the determination of PEN in tablets and
plasma11 and in pharmaceutical formulations.12
HPLC–UV methods have been used for the analysis of
PEN and its active metabolite in biological ﬂuids using
reversed-phase chromatography.13–15 HPLC method using
monolithic column was used to analyze PEN in pharmaceuti-
cals and separate it from its related substance.16 The resolution
(Rs) of this chromatographic method did not achieve the
pharmacopieal requirement needed between PEN and CAF
or between CAF and THEO3,4 but our proposed method
did. This reported method used an isocratic elution of the
mobile phase as it analyzed PEN and its related impurities.
The method did not investigate PEN under different stress
conditions as our proposed method did. A gradient elution
of the mobile phase was needed in our proposed work in order
to separate PEN from various foreign peaks appearing with
retention times (tr) close to that of PEN. The proposed method
in this paper has the advantage of being a stability indicating
method besides analyzing PEN in the presence of some of its
related impurities with the aid of DAD to conﬁrm the identity
of the appeared peaks. The linearity range of the proposed
work was suitable for analyzing PEN in different pharmaceu-
ticals and it attained lower LOD and LOQ than the monolithic
column method did.16
HPLC–MS methods were developed for the quantiﬁcation
of PEN and its metabolites in plasma17 and for the investiga-
tion of PEN degradation products in water.18.
A forced degradation study of PEN with special emphasis
on the isolation and characterization of the alkaline and oxida-
tive degradation products using HPLC and UHPLC coupled
with mass detection was found in the literature,19 but this
study did not deal with the separation of PEN from its phar-
macopeial related substances (CAF and THEO).
Recently, a novel application of chemometrics to the
chromatographic peak responses in the kinetic investigation
of Pentoxiphylline was introduced by the authors using the
non-parametric linear regression method.20 The kinetic study
of Pentoxiphylline was conducted under two different stress
conditions using DAD–HPLC with the application of
Arrhenius equation to the determination of the half life of
Pentoxiphylline in alkaline condition.20
In the present work, a stability-indicating DAD–HPLC
method was developed for the analysis of Pentoxifylline
(PEN) in the presence of its pharmacopeial related substances,
Caffeine anhydrous (CAF) and Theophylline anhydrous
(THEO). The different HPLC parameters were optimized for
the identiﬁcation and determination of PEN in its dosage form
(sustained release tablets).
This work also deals with the study of the forced degrada-
tion of PEN under various conditions including; hydrolysis
(acid, alkaline and neutral), oxidation, dry heat and photo-
decomposition. The proposed method could separate the
PEN peak from those of the different forced degradation
products.
Table 1 Gradient elution of mobile phase for the chromato-
graphic separation of PEN from its related substances and
forced degradation products.
Time (min) (A) 0.05 M KH2PO4
pH 2.3% (V/V)
(B) Methanol%
(V/V)
0–6 60 40
6–11 60 ﬁ 40 40 ﬁ 60
11 –11.5 40 ﬁ 60 60 ﬁ 40
11.5– 14 60 40
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2.1. Materials and reagents
Pentoxifylline, Caffeine anhydrous and Theophylline anhy-
drous were kindly supplied by Alexandria Company for Phar-
maceutical and Chemical Industries (Alexandria, Egypt).
Methanol used was of HPLC grade and was obtained from
LAB-SCAN (UK) while other reagents were of analytical
grade including: potassium dihydrogen phosphate and ortho-
phosphoric acid obtained from LOBA-Chemie, NaOH, HCl
and H2O2 obtained from ELNASR company-ADWIC for
chemical industries (Egypt).
2.2. Apparatus
The chromatographic separation was carried out on: a Waters
HPLC system which consists of Alliance e HPLC with a 2695
separation module consisting of a solvent management mod-
ule, a sample management module and a column oven. Em-
power 2 chromatography data software for the recording
and integration of the chromatograms. The detector was a
DAD (Photodiode Array) absorbance detector (2998 Waters
detector). The column used: A Waters Atlantis d C18
(4.6 · 250 mm, spherical particles), 5 lm particle size.
3. Preparation of standard solutions
3.1. Preparation of stock standard solutions
Astock solution of each of PENand its related substances ‘CAF
andTHEO’was prepared inmethanol to obtain a concentration
of 2 mg mL1. The solutions were kept in a refrigerator at 5 C.
3.2. Preparation of working PEN standard solutions
Working PEN standard solutions within the range of (0.04–
0.16) mg mL1 were prepared by diluting different volumes
of the stock solution into 100 mL volumetric ﬂasks with a
diluting solvent composed of 0.05 M KH2PO4 solution pH
2.3: methanol (60:40 V/V). The different working standard
solutions of PEN were directly injected into HPLC system.
3.3. Preparation of working CAF and THEO ‘related substance’
standard solutions
Working CAF and THEO standard solutions were prepared
separately by diluting 5 mL from each stock solution into
100 mL volumetric ﬂasks with the diluting solvent. Working
standard solutions, having a concentration of 0.1 mg mL1 for
each related substance, were directly injected intoHPLC system.
3.4. Preparation of working standard mixture solution of PEN
and related substances ‘CAF and THEO’
The working standard mixture of PEN, CAF and THEO solu-
tion was prepared by diluting 5 mL from each stock solution
into a 100 mL volumetric ﬂask with the diluting solvent to
obtain a ﬁnal concentration of 0.1 mg mL1 of each drug.
The solution was directly injected into HPLC system.4. Chromatographic conditions
Mobile phase: Composed of different ratios of mobile phase A
and B, Table 1.
Mobile phase A: 0.05 M KH2PO4, adjusted at pH 2.3.
Mobile phase B: Methanol.
Flow rate: 1 mL min1.
Temperature: Ambient.
Detection wavelength: Using photodiode array detector set
at 273 nm.
Injection volume: 20 lL.
5. Analysis of PEN dosage form (Pental & Pexal 400 SR
tablets)
Test solutions were prepared by weighing 20 tablets of each of
Pental or Pexal SR tablets (labeled to contain 400 mg of
PEN per tablet) to determine their average weight, then an
amount of powdered tablets equivalent to 100 mg of PEN
was accurately weighed and transferred into 50 mL volumetric
ﬂasks, 40 mL of methanol was added, then the solutions were
sonicated for 15 min and the volume was adjusted with meth-
anol to obtain stock test solutions having a concentration of
2 mg mL1 for each dosage form. The stock test solutions were
ﬁltered, then 5 mL was transferred into 100 mL volumetric
ﬂasks and the volumes were completed with the diluting sol-
vent to obtain working test solutions of ﬁnal concentration
of 0.1 mg mL1 for each dosage form. These ﬁnal solutions
were directly injected into HPLC system.
6. Forced degradation study
6.1. Acidic hydrolysis
A volume of 5 mL from the stock solution of PEN was mixed
with 5 mL of 2 N HCl into a 250 mL conical ﬂask, heated in a
water bath adjusted at 70 C for 4 h, cooled, then neutralized
with 2 N NaOH. The solution was transferred quantitatively
into a 100 mL volumetric ﬂask, completed to volume with
diluting solvent, mixed well, ﬁltered and injected into HPLC
system using the chromatographic conditions stated.
6.2. Alkaline hydrolysis
A volume of 5 mL from the stock solution of PEN was mixed
with 5 mL of 2 N NaOH into a 250 mL conical ﬂask, heated in
a water bath adjusted at 70 C for 4 h, cooled, then neutralized
with 2 N HCl, then the procedure was continued as described
under Acidic hydrolysis.
Figure 2 Variation of retention times as a function of percentage
of methanol in the mobile phase.
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A volume of 5 mL from the stock solution of PEN was mixed
with 5 mL of H2O into a 250 mL conical ﬂask, heated in a
water bath adjusted at 70 C for four hours, cooled then trans-
ferred quantitatively into a 100 mL volumetric ﬂask and the
procedure was continued as described under Acidic hydrolysis.
6.4. Photo-degradation
A volume of 5 mL from the stock solution of PEN was mixed
with 5 mL of H2O into a 250 mL conical ﬂask, exposed to sun-
light for eight hours then transferred quantitatively into a
100 mL volumetric ﬂask and the procedure was continued as
described under Acidic hydrolysis.
6.5. Oxidative degradation
A volume of 5 mL from the stock solution of PEN was mixed
with 5 mL of 30% solution of H2O2 into a 250 mL conical
ﬂask, heated in a water bath adjusted at 70 C for 4 h, cooled
then transferred quantitatively into a 100 mL volumetric ﬂask
and the procedure was continued as described under Acidic
hydrolysis.Figure 3 HPLC chromatogram of 0.1 mg mL1 of standard mixtu
anhydrous and Theophylline anhydrous) in a ratio of 1:1:1 using the6.6. Dry heat
About 500 mg of PEN working standard was weighed into a
petri-dish, inserted in an oven previously adjusted at 105 C,
left for 4 h, and then cooled. An amount of the powder was
weighed and dissolved in MeOH to obtain a solution having
a concentration of 2 mg mL1 of PEN, then 5 mL from the
previous solution was accurately transferred into a 100 mL
volumetric ﬂask and the procedure was continued as described
under Acidic hydrolysis.7. Results and discussion
7.1. Optimization of chromatographic conditions
7.1.1. Effect of methanol ratio
The mobile phase used was a mixture of different ratios of
0.05 M potassium dihydrogen phosphate adjusted at pH 2.3
(as mobile phase A) and MeOH (as mobile phase B) in the gra-
dient elution mode. As a preliminary trial, the standard mix-
ture solution of PEN, CAF and THEO in a concentration of
0.1 mg mL1 of each was injected into a Hypersil C18 column
and eluted with different proportions of MeOH and 0.05 M
KH2PO4 pH 2.3 in the isocratic mode. As can be seen in
Fig. 2, MeOH less than 40% in the mobile phase caused the
parent drug peak to elute very late. However, 40% MeOH in
the mobile phase provided a good separation between the drug
(PEN) and its related substances (THEO and CAF) but PEN
was still eluted late with a low number of theoretical plates (N).
By increasing the percentage of MeOH in the mobile phase
PEN was eluted rapidly with a high number of theoretical
plates but the related substance peaks became overlapped.
As a result, a gradient elution (Table 1) was considered to be
more suitable for this kind of separation providing a good
separation of the related substance peaks with a reasonable
retention time of the PEN peak, good peak shape and a high
number of theoretical plates.re solution of Pentoxifylline and its related substances (Caffeine
optimized chromatographic conditions.
Table 2 Evaluation of the accuracy for the determination of
Pentoxifylline by the proposed HPLC method according to
ICH guidelines.
Nominal value(mg mL1) Mean recovery,%a±SD
0.08 100.35± 0.975
0.1 99.42 ± 0.418
0.12 99.35 ± 0.590
Grand meanb ± Pooled SDc 99.71%± 0.699
S.Ed 0.233
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The effect of column type (packing material) on the separation
and determination of PEN was investigated using three differ-
ent C18 columns (Hypersil BDS, X-Terra and Atlantis col-
umn). It was found that Atlantis column gave the most
suitable resolution between CAF and THEO peaks (>4)
according to the pharmacopeial requirement while the other
columns cause the peaks of the related substances either to
be overlapped or to have unsuitable resolution (<4).a Mean of recovery,% of three replicates at each concentration
level.
b Mean of recovery of the three different concentration levels.
c Pooled standard deviation of all recoveries for the three dif-
ferent concentration levels.
d Standard error of the mean.7.1.3. HPLC method development
Gradient elution was used for the determination of PEN and
its separation from its related impurities ‘‘CAF’’ and ‘‘THEO’’
with good chromatographic characteristic, (Fig. 3). The use of
gradient elution was proven to be more advantageous over iso-
cratic elution because it resulted in shorter retention time for
the PEN peak and helped in the separation of PEN from its
related substances and degradation products.
The HPLC method achieved a good resolution of PEN, CAF
and THEO (good resolution of 19.56 and 4.13 and selectivity val-
ues of 2.08 and 1.36, respectively) within reasonable run time (suit-
able capacity factors of 3.29, 1.58 and 1.15, respectively). In
addition, high column efﬁciencywas indicated from the large num-
ber of theoretical plates. The degree of peak symmetry was also
evaluated using the tailing factor which did not exceed the critical
value (1.2) indicating acceptable degree of peak asymmetry.
7.2. Method validation
The method was validated according to ICH guidelines.21 The
following validation characteristics were addressed:
7.2.1. Linearity
An excellent linearity (r= 0.9999) was obtained for PEN in the
linearity range of 0.04–0.16 mg mL1with a regression equation
of y= 37321738 ·+ 513165. A good regression line22 showing
a high (r) value and a low (Sy/x) value of 112 was obtained.
7.2.2. Detection and quantitation limits
Detection (LOD) and quantitation limits (LOQ) were calcu-
lated by using the residual standard deviation of the regression
line (Sy/x) of the calibration curve and its slope (b).
23 LOD andTable 3 Evaluation of the robustness for the determination of Pe
guidelines.
Parameters Recovery,%a
pH of phosphate buﬀer (2.2, 2.3 and 2.4) 2.2 100.08
2.3* 100.53
2.4 99.77
Temperature (24, 25 and 26 C) 24 100.36
25* 100.76
26 100.22
* Analytical pH and temperature stated in the proposed method.
a The recovery of the Pentoxifylline sample at each pH value and temp
b % change in the recovery from the analytical point.
c The mean of recoveries of the Pentoxifylline sample at different
Pentoxifylline.
d Standard deviation of the recoveries of the Pentoxifylline sample at t
e Percentage relative standard deviation of the Pentoxifylline sample atLOQ which were calculated by this statistical method were
found to equal 9 · 106 and 3 · 105mg mL1, respectively.
7.2.3. Accuracy
The accuracy of the proposed HPLC method was evaluated by
analyzing three different concentrations of PEN working stan-
dard solutions (prepared by adding different volumes of PEN
stock solution to placebo). These solutions were within the lin-
earity range, each of three replicates. Accuracy was expressed
as the recovery%21 and standard error for PEN. Satisfactory
recovery% with small standard error and pooled standard
deviation were obtained, Table 2.
7.2.4. Precision
7.2.4.1. Repeatability (intra-day). The intra-day precision for
the determination of PEN was carried out by analyzing dosage
form sample solutions (Pental 400 SR Tablets) prepared
at 100%of test concentration stated in themethod (0.1 mg mL1)
using the proposedmethod,within the same laboratory, using the
same analyst, with the same equipment, on the same day. Repeat-
ability was assessed using six determinations each injected twice
and the obtained RSD% was 0.710%.
7.2.4.2. Intermediate precision (inter-day). The inter-day preci-
sion for the determination of PEN was carried out as under
repeatability but on three consecutive days, at each day thentoxifylline by the proposed HPLC method according to ICH
% Changeb Mean recovery,%c SDd RSD,%e
– 0.448%
– 100.13 0.382 0.382
– 0.756%
0.397%
– 100.45 0.280 0.279
0.536%
erature for a concentration of 0.1 mg mL1 Pentoxifylline.
pH values and temperatures for a concentration of 0.1 mg mL1
he three pH values and temperatures.
the three pH values and temperatures.
Figure 4 HPLC chromatogram (a) of working standard solution of Pentoxifylline 0.1 mg mL1 after alkaline hydrolysis with 2 N NaOH
and its peak purity plot (b) and peak proﬁle (c).
216 M.A. Korany et al.determination was done twice (n= 6). The obtained pooled SD
andRSD%were 0.477 and 0.472, respectively. The criterion for
intra-day and inter-day precisions is a RSD less than 2%.7.2.5. Robustness
Robustness of the proposed method was evaluated by analyz-
ing PEN dosage form (Pental 400 SR Tablets) at the same
Figure 5 HPLC chromatogram (a) of working standard solution of Pentoxifylline 0.1 mg mL1 after oxidative degradation with 30%
H2O2 and its peak purity plot (b) and peak proﬁle (c).
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variation of the selected parameters. The low values of RSD%
of the recoveries% after introducing small changes in the meth-
od parameters indicated the robustness of the method, Table 3.
7.2.6. Speciﬁcity
It was found that the normally existing excipients and addi-
tives did not interfere with the applied HPLC method. So,
pharmaceutical preparations containing PEN (Pental 400SR Tablets and Pexal 400 SR Tablets) were successfully ana-
lyzed by the proposed HPLC method.7.3. Forced degradation study
The effect of the presence of different forced degradation
products on the purity of PEN peak was studied. The purity
of the PEN peak was conﬁrmed using the DAD by obtaining
purity angle smaller than purity threshold. Also the peak
Table 4 Analysis of Pentoxifylline (PEN) in different phar-
maceutical preparations by external standard method.
Dosage form External standard method
Recovery%a Mean recovery%±RSD%b
Pental 400 SR Tablets 101.18 101.56 ± 0.529
101.94
Pexal 400 SR Tablets 103.59 103.12 ± 0.645
102.65
a The recovery% of each determination using a concentration of
0.1 mg mL1 of Pentoxifylline in different dosage forms.
b The mean recovery%±RSD% of duplicate determinations.
218 M.A. Korany et al.purity plots and peak proﬁle of PEN indicated the purity of
the peak as a result the method was found to be stability-
indicating.
PEN was not affected by acidic, neutral hydrolysis,
photo-degradation or dry heat. For alkaline hydrolysis,
the peak of PEN was nearly completely destroyed and it
was eluted far from the other degradation peaks (Fig. 4a).
The purity angle (0.202) was smaller than purity threshold
(0.391) which indicates the purity of the peak. Fig. 4 b &
c, show the peak purity plot and peak proﬁle of PEN which
conﬁrms the purity of the peak. PEN was partially
degraded following the treatment with 30% H2O2 as the
peak area decreased by 13% (Fig. 5a) and eluted far from
the
other degradation peak. The purity angle (0.145) was smal-
ler than purity threshold (0.390) which indicates the purity
of the PEN peak. Fig. 5 b & c show the peak purity plot
and peak proﬁle of PEN which conﬁrms the purity of the
peak.
7.4. Analysis of pharmaceutical formulation
Using the proposed HPLC method, the determination of PEN
in its dosage form (sustained released tablets) was carried out.
PEN was analyzed in different brands including Pental 400
SR Tablets and Pexal 400 SR Tablets. Satisfactory results
were obtained for each dosage form, which are in a good
agreement with the label claims, 101.56 ± 0.529% and
103.12 ± 0.645% for Pental 400 SR Tablets and Pexal
400 SR Tablets, respectively (Table 4).
8. Conclusions
In this study, a simple, selective and reliable DAD–HPLC
method was developed for the assay of PEN in pharmaceu-
tical preparations. Selectivity was demonstrated by the sep-
aration of PEN from its related substances and forced
degradation products. Reliability is guaranteed by the re-
sults of testing the various validation parameters of the
method and the successful application to commercial dosage
forms.
The proposed method used the widely spread and conven-
tional DAD as a tool for peak identity and purity conﬁrma-
tion. Therefore, the developed method can be recommended
for routine analysis and for checking quality during stability
studies.9. Conﬂict of interest
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